Innovation in oncology is facing a significant hurdle when it comes to identifying novel targets, this is the belief of Germany and Switzerland-based DISCO Pharmaceuticals, which plans to overcome the obstacle with its surfaceome technology
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?